<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00398996</url>
  </required_header>
  <id_info>
    <org_study_id>CAPRISA 003</org_study_id>
    <nct_id>NCT00398996</nct_id>
  </id_info>
  <brief_title>A Study to Compare Three Existing Starting Points of Anti-Retroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients</brief_title>
  <acronym>SAPIT</acronym>
  <official_title>Study to Compare Three Existing Starting Points of ART Initiation in HIV/TB Co-infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for the AIDS Programme of Research in South Africa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre for the AIDS Programme of Research in South Africa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label study comparing three existing treatment strategies of ART
      initiation in HIV/TB co-infected patients:

      Group 1: early initiation of ART with TB treatment, Group 2: initiation of ART upon
      completion of the intensive phase of TB treatment, Group 3: initiation of ART upon completion
      of the continuation phase of TB treatment

      Approximately 700 men and women â‰¥ 18 years of age with documented HIV infection and
      smear-positive pulmonary TB patients will be enrolled. Eligible TB/HIV co-infected patients
      will be offered antiretroviral therapy (ART), starting at one of the three time points listed
      above through the CAPRISA AIDS treatment programme which includes extensive counselling and
      adherence support. The study participants will be followed for 18 months to assess the
      primary study endpoint of the optimal time to start antiretroviral therapy (ART) in patients
      on tuberculosis (TB) treatment by comparing clinical status (CD4+ cell count, viral load,
      opportunistic infections.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To measure the incidence of progression to AIDS defining illness or mortality</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>A comparison of CD4+ cell count, viral load, opportunistic infections across the 3 study arms</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">642</enrollment>
  <condition>HIV Infections</condition>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>1 - Early integrated-therapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>antiretroviral therapy to be initiated within 4 weeks of starting tuberculosis treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 - Late integrated-therapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>antiretroviral therapy to be initiated within 4 weeks of completing the intensive phase of tuberculosis treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 - Sequential-therapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Antiretroviral therapy to be initiated within 4 weeks after completing tuberculosis treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Early versus intermediate versus late initiation of ART</intervention_name>
    <description>Initiation of once daily ddI (400 / 250mg), 3TC (300mg) and EFV (600mg)during the intensive phase of TB therapy or during the continuation phase of TB therapy or once TB therapy has been completed</description>
    <arm_group_label>1 - Early integrated-therapy group</arm_group_label>
    <arm_group_label>2 - Late integrated-therapy group</arm_group_label>
    <arm_group_label>3 - Sequential-therapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infected patients co-infected with TB

          -  Receiving any one of the standard anti-TB therapy regimens

          -  All patients must agree to use contraception since they will be on efavirenz.

        Exclusion Criteria:

          -  Entry into the treatment programme is based on a clinical assessment and should
             patients not be clinically eligible to maintain a treatment regimen,their entry may be
             deferred or precluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salim S Abdool karim, MBChB, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CAPRISA, University of KwaZulu-Natal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CAPRISA eThekwini Clinical Research Site</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <link>
    <url>http://www.caprisa.org/</url>
    <description>Centre for the AIDS Programme of Research in South Africa's website</description>
  </link>
  <reference>
    <citation>Abdool-Karim SS, Abdool-Karim Q, Friedland G, Lalloo U, El-Sadr WM; START project. Implementing antiretroviral therapy in resource-constrained settings: opportunities and challenges in integrating HIV and tuberculosis care. AIDS. 2004 Apr 30;18(7):975-9. Review.</citation>
    <PMID>15096799</PMID>
  </reference>
  <results_reference>
    <citation>Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T, Nair G, Bamber S, Singh A, Khan M, Pienaar J, El-Sadr W, Friedland G, Abdool Karim Q. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010 Feb 25;362(8):697-706. doi: 10.1056/NEJMoa0905848.</citation>
    <PMID>20181971</PMID>
  </results_reference>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2006</study_first_submitted>
  <study_first_submitted_qc>November 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2006</study_first_posted>
  <last_update_submitted>March 23, 2011</last_update_submitted>
  <last_update_submitted_qc>March 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director: Prof Salim S Abdool Karim</name_title>
    <organization>CAPRISA</organization>
  </responsible_party>
  <keyword>antiretroviral therapy</keyword>
  <keyword>HIV</keyword>
  <keyword>Opportunistic infections</keyword>
  <keyword>CD4</keyword>
  <keyword>Viral load</keyword>
  <keyword>TB/HIV co infection</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

